Chronic Lymphocytic Leukemia Clinical Trials
Here are the 6 most popular medical studies for chronic lymphocytic leukemia
Kinase Inhibitor
Triple Drug Therapy for Chronic Lymphocytic Leukemia
This trial is testing a new combination of drugs to treat leukemia. The drugs are ibrutinib, fludarabine, and pembrolizumab. The trial is open to patients with leukemia who have not responded to other treatments.
Popular filter options for chronic lymphocytic leukemia trials
CLL Clinical Trials
View 87 CLL medical studies.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
Mantle Cell Lymphoma Clinical Trials
View 52 Mantle Cell Lymphoma medical studies.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
CAR T-cell Therapy
JCAR017 for Chronic Leukemia or Lymphoma
This trial is testing a new drug, JCAR017, to see if it is safe and effective at treating leukemia in adults. The trial will be conducted in two parts, with a separate cohort testing the drug in combination with ibrutinib or venetoclax. All subjects will be monitored for safety and efficacy, and the pharmacokinetics of JCAR017 will be studied.
CD19 Positive Clinical Trials
View 9 CD19 positive medical studies.
CAR T-cell Therapy
JCAR017 for Chronic Leukemia or Lymphoma
This trial is testing a new drug, JCAR017, to see if it is safe and effective at treating leukemia in adults. The trial will be conducted in two parts, with a separate cohort testing the drug in combination with ibrutinib or venetoclax. All subjects will be monitored for safety and efficacy, and the pharmacokinetics of JCAR017 will be studied.
CAR T-cell Therapy
Autologous HuCD19 (Anti-CD19) CAR T cells for Chronic Lymphocytic Leukemia
"This trial aims to test a new treatment called anti-CD19 CAR T cell therapy for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Immunomodulatory Agent
Triple Therapy for CLL/SLL
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
CD20 Positive Clinical Trials
View 8 CD20 positive medical studies.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This trial is testing a new cancer drug, BTCT4465A (Mosunetuzumab), given alone or with another drug, atezolizumab. It is for people with B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia that has come back or does not respond to treatment.
BTK Inhibitor
Acalabrutinib for Chronic Lymphocytic Leukemia
This trial is testing a new medication, acalabrutinib, to see if it is safe and effective in treating people with chronic lymphocytic leukemia. The trial will last for approximately 72 months and will enroll 600 participants.
B-cell lymphoma-2 (BCL-2) inhibitor
Venetoclax + Ibrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
Phase 3 Chronic Lymphocytic Leukemia Clinical Trials
View 95 phase 3 chronic lymphocytic leukemia medical studies.
Kinase Inhibitor
Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Chronic B-Cell Leukemia
This trial is comparing two treatments for leukemia, one with ibrutinib and venetoclax, and the other with obinutuzumab and chlorambucil. The goal is to see which of these treatments results in better progression-free survival, as assessed by an independent review committee.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Monoclonal Antibodies
Obinutuzumab + Venetoclax vs. Chlorambucil for Chronic Lymphocytic Leukemia
This trial is testing a new combination of drugs for people with CLL and other medical conditions. The trial will last about a year, with follow-up for up to 9 years.
Chronic Lymphocytic Leukemia Clinical Trials With No Placebo
View 95 chronic lymphocytic leukemia medical studies that do not have a placebo group.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
View More Chronic Lymphocytic Leukemia Trials
See another 68 medical studies focused on chronic lymphocytic leukemia.
Frequently Asked Questions
Introduction to chronic lymphocytic leukemia
What are the top hospitals conducting chronic lymphocytic leukemia research?
When it comes to cutting-edge clinical trials for chronic lymphocytic leukemia (CLL), several hospitals across the United States are leading the charge. In Houston, M D Anderson Cancer Center shines with 11 ongoing CLL trials and an impressive track record of 48 completed trials dedicated to this condition. Their commitment dates back to their first recorded CLL trial in 1998, demonstrating long-standing expertise in tackling this challenging disease. Similarly, Memorial Sloan Kettering Cancer Center in New york boasts seven active CLL trials and a total of 35 previously conducted studies since embarking on their first trial in 2005.
Moving westward to Seattle, the Fred Hutchinson Cancer Research Center is making significant strides with six active clinical trials focused on CLL. They have contributed extensively to understanding and treating this blood cancer over the years, having initiated their inaugural trial as early as 1995. Meanwhile, on the West Coast in Duarte, California, both City of Hope Comprehensive Cancer Center and its counterpart City of Hope are actively engaged in advancing knowledge about CLL through innovative research protocols. The former currently has six ongoing clinical trials while having undertaken thirteen previous investigations since recording its first CLL trial in 2000. On the other hand, City of Hope contributes five active clinical tests towards finding better treatment options for patients battling this disease; they started conducting these insightful inquiries only fourteen years ago with a debut experiment logged under "chronic lymphocytic leukemia" throughout all-time tally reaching twenty-one.
These top-tier medical institutions represent beacons of hope for individuals affected by chronic lymphocytic leukemia. Through constant dedication and groundbreaking research efforts at these renowned hospitals spanning across different corners of America - from bustling cities like Houston and New York to picturesque locations like Seattle and Duarte - we can remain optimistic that breakthroughs are within reach that will pave new pathways towards more effective treatments for those living with this challenging form of blood cancer
Which are the best cities for chronic lymphocytic leukemia clinical trials?
When it comes to chronic lymphocytic leukemia clinical trials, several cities have emerged as key players in advancing research and treatment options. Denver, Colorado leads the way with 43 active trials focusing on Ibrutinib, Quality-of-Life Assessment, and other innovative approaches. New york, New York and Houston, Texas follow closely behind with 32 ongoing studies exploring promising treatments like Pirtobrutinib, JNJ-80948543, JNJ-67856633, and Ibrutinib. Anchorage, Alaska also makes a mark with 25 active trials investigating Ibrutinib and Quality-of-Life Assessment. Lastly, Duarte California contributes to advancements through its 20 ongoing trials studying therapies such as JCAR017 (lisocabtagene maraleucel), ibrutinib, and JNJ-80948543. Together these cities offer individuals fighting chronic lymphocytic leukemia access to cutting-edge clinical trials that pave the way for improved care outcomes.
Which are the top treatments for chronic lymphocytic leukemia being explored in clinical trials?
Exciting advancements in the realm of chronic lymphocytic leukemia (CLL) are taking shape through rigorous clinical trials. Leading the charge is ibrutinib, showcasing its potential in 10 active CLL trials and accumulating an impressive total of 87 all-time trials since its introduction in 2012. Not far behind is acalabrutinib, making waves with eight ongoing clinical trials and a solid foundation of 32 previous CLL studies since its debut in 2014. Venetoclax also shines as a promising treatment option, currently being explored in four active CLL trials, alongside an extensive history of 78 all-time investigations starting from 2012. Another contender on the forefront is pirtobrutinib—although relatively new—with four active and eight all-time CLL trials recorded since it was first listed in 2018. These treatments hold immense potential to transform the landscape for patients fighting against this challenging disease.
What are the most recent clinical trials for chronic lymphocytic leukemia?
Recent clinical trials for chronic lymphocytic leukemia offer new hope and potential treatment options. One trial explores the use of a combination treatment consisting of tafasitamab, obinutuzumab, and acalabrutinib in Phase 1. Another study investigates the efficacy of nemtabrutinib combined with Venetoclax in Phase 3. Additionally, an ongoing Phase 2 trial called Arm I (GEO-CM04S1) aims to evaluate a specific treatment approach for this type of leukemia. Furthermore, another promising Phase 2 trial examines the effectiveness of combining tafasitamab and zanubrutinib as a therapeutic option. Lastly, Acalabrutinib is being studied in a separate Phase 2 trial as a potential targeted therapy for chronic lymphocytic leukemia patients. These advancements hold great promise for improving outcomes and quality of life for those affected by this challenging disease.
What chronic lymphocytic leukemia clinical trials were recently completed?
Recent advancements in clinical trials for chronic lymphocytic leukemia (CLL) have been promising, offering hope to patients battling this complex disease. Noteworthy completed trials include the investigation of PBCAR20A by Precision BioSciences, Inc., concluded in March 2020. Mayo Clinic also achieved significant progress with their trial on Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, finalized in April 2019. Additionally, the University of Rochester successfully completed a trial examining the efficacy of the Shingrix vaccine in February 2019. These innovative studies highlight the commitment and dedication of researchers towards improving CLL treatment options and ultimately enhancing patient outcomes.